An Open Letter to WHO on access to DRV/r 400/50 mg in LMICs

On behalf of community stakeholders, Afrocab Treatment Access Partnership shared an open letter with the WHO as a follow-up to a community and advocates sign-on letter released on 3rd December 2022.  The statement called on WHO and others to accelerate access to DRV/r in the second line of HIV treatment.

The community notes that since the release of the first statement, there have not been any visible concerted efforts to engage countries and PLHIV when DRV/r will be made available in LMICs i.e. be made a preferred regimen for HIV 2L treatment, given that the 400/50 mg formulation has been known to LMICs for 18 months.

We remind WHO that PLHIV need your leadership to guide countries with a transition plan for DRV/r introduction in LMICs and remove LPV/r as has happened in countries in the north.

The open letter is below:

Published: March 2, 2023